{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-022592","form_type":"8-K","ticker":"RXST","cik":"0001111485","company_name":"RxSight, Inc.","filed_at":"2022-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.646586+00:00","generated_at":"2026-06-22T05:00:16.126136+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"RxSight Q3 revenue $12.6M (+118% YoY); raises FY22 guidance to $47-48M","bullets":["Q3 2022 revenue of $12.6M, up 118% YoY; LDD installed base reached 343 units (113% YoY increase).","Sold 6,595 LALs (+234% YoY); gross margin improved to 42.5% vs 23.2% in Q3 2021.","Raised FY2022 revenue guidance to $47-48M (from $44-46M); gross margin guidance raised to 41-43%.","Net loss of $(16.8)M or $(0.61)/share vs $(12.7)M or $(0.68)/share in Q3 2021.","Cash & investments $112.8M; long-term debt $40.0M; operating expense guidance lowered."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-022592","json":"https://secwatch.observer/filing/0000950170-22-022592.json","markdown":"https://secwatch.observer/filing/0000950170-22-022592.md","text":"https://secwatch.observer/filing/0000950170-22-022592.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1111485/000095017022022592/0000950170-22-022592-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1111485/000095017022022592/rxst-20221107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T05:00:16.126136+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a92ac686117236e052d1700ea872a30c47e7f3c3","claim":"RxSight, Inc. reported three and nine months ended September 30, 2022 results: revenue $12.6 million, net income $(16.8) million, EPS $(0.61) per basic and diluted share. Guidance raised.","evidence_excerpt":"cataract surgery, today reported financial results for the three and nine months ended September 30, 2022. Key Quarterly Highlights: • Delivered third quarter 2022 revenue of $12.6 million, an increase of 118% compared to the third quarter of 2021, reflecting: • The sale of 49 Light Delivery Devices (LDDTMs), representing a 58% unit increase from the third quarter","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1111485/000095017022022592/0000950170-22-022592-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and nine months ended September 30, 2022"},{"label":"Revenue","value":"$12.6 million"},{"label":"Net income","value":"$(16.8) million"},{"label":"EPS","value":"$(0.61) per basic and diluted share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}